Related Experiment Videos
The transition from relapsing-remitting MS to irreversible disability: clinical evaluation
M Trojano1, D Paolicelli, A Bellacosa
1Department of Neurological and Psychiatric Sciences, University of Bari, Piazza Giulio Cesare 11, I-70124, Bari, Italy.
Summary
The transition to progressive multiple sclerosis (MS) is a major challenge, with most patients experiencing irreversible disability. Understanding the mechanisms behind this progression is crucial for developing new treatments.
Area of Science:
- Neuroimmunology
- Clinical Neurology
- Disease Progression
Background:
- The progression of multiple sclerosis (MS) to a secondary progressive phase is a significant clinical event.
- Approximately 90% of relapsing-remitting MS patients develop secondary progressive MS within 20-25 years.
- This transition is marked by a distinct clinical phenotype and reduced responsiveness to anti-inflammatory therapies.
Purpose of the Study:
- To review clinical studies on the mechanisms driving irreversible disability in MS.
- To understand the shift in therapeutic responsiveness during disease progression.
Main Methods:
- Literature review of clinical studies.
- Analysis of findings on MS disease mechanisms.
Main Results:
- Identified key mechanisms contributing to irreversible disability in MS.
- Highlighted the change in treatment efficacy during disease progression.
Conclusions:
- Further research into MS progression mechanisms is essential.
- Developing strategies to address irreversible disability is a priority for MS patient care.